ProCE Banner Activity

Myeloma XI: Exploring Optimal Duration of Lenalidomide Maintenance After ASCT From Phase III Trial

Slideset Download
Conference Coverage

Data support improved PFS with continued lenalidomide maintenance beyond 4-5 years in patients with newly diagnosed multiple myeloma and for at least 3 years in patients with sustained MRD negativity.

Released: December 19, 2022

Expiration: December 18, 2023

No longer available for credit.

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

AbbVie

Amgen

AstraZeneca

Epizyme

GSK

Incyte Corporation

Jazz Pharmaceuticals

Karyopharm Therapeutics Inc.

Novartis Pharmaceuticals Corporation

Sanofi

Seagen